Across TCGA pan-cancer cohorts, DXO Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DXO data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DXO Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DXO expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.
STAD, COAD, and LUSC are the cancer types where DXO Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.